Prof Hans Gelderblom speaks to ecancer at the 2019 EORTC Groups Annual Meeting (EGAM) about the discussions that took place in the EORTC's Soft Tissue and Bone Sarcoma group.
Prof Gelderblom explains the designs of three trials that are have taken place in the group. These include the ALT-GIST trial which examined the effect of imatinib and regorafenib on progression-free survival for gastrointestinal stromal tumours (GIST).
Furthermore, he also mentioned the phase-II CABOGIST trial which aimed to evaluate the safety and activity of cabozantinib in patients with metastatic GIST and the STRASS study that administered pre-operative radiotherapy to retroperitoneal soft tissue sarcoma patients.
Prof Gelderblom also revealed details of a new trial that is under development and will focus on the use of combination chemotherapy for leiomyosarcoma.
Due to the diversity of sarcoma subtypes, Prof Gelderblom believes trials should be conducted with collaborators across Europe, in order to investigate these more rare subtypes.